Wealth Enhancement Trust Services’s ARS Pharmaceuticals SPRY Stock Holding History

Wealth Enhancement Trust Services’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16	Buy	+2	New	+$17	﹤0.01%	1509

Other funds holding SPRY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

Wealth Enhancement Trust Services's SPRY Position: Q2 2026 in Review

Wealth Enhancement Trust Services opened a new position in ARS Pharmaceuticals (SPRY) in Q2 2026: 2 shares worth $16. The stake represents ﹤0.01% of the portfolio and ranks #1509 among its holdings.

109 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

Wealth Enhancement Trust Services held 2 shares of ARS Pharmaceuticals worth $16 as of Q2 2026.
ARS Pharmaceuticals was a new Wealth Enhancement Trust Services position in Q2 2026.
ARS Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Trust Services's portfolio in Q2 2026, its #1509 holding.
109 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q2 2026, filed 15 Jul 2026.